Psychoactive Substance Abuse
Psychoactive Substance Abuse screening by GIA®, powered by digitalhumanOS™, uses Voice AI, Computer Vision, and Speech Biomarkers to detect psychoactive substance abuse through a single patient conversation. Screening performance: 75.1% accuracy. Screening takes under 5 minutes with results in 60 seconds.
Unaddressed substance abuse hinders recovery and jeopardizes patient safety and long-term health.
Substance abuse can significantly complicate recovery in post-acute care settings. Early screening allows for timely intervention, preventing relapse and improving patient outcomes.
Key Facts
- Screening Time
- Under 5 minutes
- Results
- 60 seconds
- Modalities
- Voice + Vision + Speech
- Registration
- FDA-Registered
- Status
- Live
This content is intended for informational purposes and does not constitute medical advice. Editorially reviewed by David Kaiser, CEO of Scienza Health, for accuracy in post-acute care operations.
About Psychoactive Substance Abuse screening.
How does the system detect potential substance abuse?
The AI analyzes vocal patterns, speech characteristics, and behavioral cues indicative of substance use.
What safeguards are in place to protect patient privacy?
All data is anonymized and processed securely, adhering to strict privacy regulations.
How does this screening integrate with addiction treatment programs?
The results can be used to connect patients with appropriate treatment resources and support services.
The science behind Psychoactive Substance Abuse screening.
Applied research demonstrates voice biomarker technology reliably identifies stress and vulnerability indicators in conversational settings — with direct applications to clinical care environments.
Addressing Turnover and Vulnerability in Call Centers Case Study (2024-07)View all peer-reviewed research. See how GIA® screens for Psychoactive Substance Abuse in skilled nursing facilities.
The Operator's Guide to Multimodal Clinical AI
What administrators, DONs, and regional operators need to know before evaluating clinical AI platforms. Covers EHR integration, staffing impact, reimbursement codes, and deployment timelines.